Nano preparation for treating bacterial infection of diabetic wounds as well as preparation method and application of nano preparation
By developing the nanoformula MmX-PEG-GOx, the metal non-metallic nanomaterial with cubic hollow structures works synergistically with glucose oxidase, the broad-spectrum bactericidal problem of diabetic wound infection is solved, and effective killing of drug-resistant bacteria and biological Compatibility avoids the occurrence of bacterial resistance.
Patent Information
- Application Number
- CN202411102295.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-26
AI Technical Summary
Existing antibiotic treatments have led to increased bacterial resistance, making it difficult to effectively treat diabetic wound infections, and a single copper-based material has poor bacterial killing effect.
Develop a nanoformula MmX-PEG-GOx, which uses metal non-metallic nanomaterials with cubic hollow structures (such as CuSe, CuS, CuTe, Ag2Se, FeSe) to work synergistically with glucose oxidase to produce hydrogen peroxide and reactive oxygen species, effectively killing Dead bacteria.
The broad-spectrum bactericidal effect on Staphylococcus aureus, E. coli and drug-resistant bacteria has been achieved, reducing bacterial resistance, and has good biocompatibility and stability.
Smart Images

Figure CN119015400A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of antibacterial materials, in particular to a nano preparation and a preparation method thereof and application thereof in preparing a medicine for treating bacterial infection of diabetic wounds. Background Art
[0002] Diabetes is a common disease, and chronic wounds are one of the most serious complications of diabetes. Due to high blood sugar levels in the wounds, insufficient blood supply, lack of oxygen and other problems, patients are extremely susceptible to bacterial infection, forming chronic wounds that are difficult to heal.
[0003] Currently, antibiotic treatment has become a common method to fight pathogenic bacteria infections. However, the abuse of antibiotics can cause bacteria to develop drug resistance. With the continuous emergence of drug-resistant strains (such as methicillin-resistant Staphylococcus aureus), it has become increasingly difficult to treat infections.
[0004] This requires the continuous introduction of new antibiotics to solve the problem. If left unchecked, it may lead to the terrible consequence that bacteria become resistant to all antibiotics.
[0005] Therefore, there is an urgent need for new broad-spectrum antibacterial materials that will not develop drug resistance to solve the problems faced in the existing technology.
[0006] In recent years, copper-based nanomaterials have become one of the research hotspots due to their strong absorption in the near-infrared region, good biocompatibility and excellent antibacterial properties. However, a single copper-based material cannot achieve the expected effect in killing bacteria.
[0007] Therefore, this field has been committed to studying the purpose of synthesizing copper-based and selenium-based nanomaterials with good antibacterial activity and biocompatibility to resist common bacteria (Gram-positive, Gram-negative bacteria and drug-resistant bacteria) through effective preparation methods, in order to provide a reference for clinical application. Summary of the invention
[0008] The technical problem to be solved by the present invention is to provide a new type of inorganic modified material, which has a broad-spectrum sterilization effect and does not cause bacteria to develop drug resistance.
[0009] One of the purposes of the present invention is to provide a nano preparation that has a broad-spectrum sterilization effect while not causing bacteria to develop drug resistance;
[0010] The second object of the present invention is to provide a method for preparing the above-mentioned nanoformulation;
[0011] The third object of the present invention is to provide the use of the above-mentioned nanoformulation for preparing a drug for treating bacterial infection of diabetic wounds.
[0012] The present invention discloses a nano preparation of a drug for treating bacterial infection of diabetic wounds, which is M mX-PEG-GOx;
[0013] The M m X is a cubic hollow structure;
[0014] The M is a metal element, m is 1 or 2, and the selection of m is based on the valence state of the metal M;
[0015] The X is selected from non-metallic elements S, Se, and Te.
[0016] Preferably, M is selected from Cu, Ag, Fe.
[0017] Preferably, the nano preparation adopts a cubic hollow structure.
[0018] Preferably, the nanoformulation is selected from CuSe-PEG-GOx, CuS-PEG-GOx, CuTe-PEG-GOx, TeSe-PEG-GOx, Ag 2 Se-PEG-GOx, FeSe-PEG-GOx.
[0019] The invention also discloses application of the nano preparation in preparing medicine for treating bacterial infection of diabetic wounds.
[0020] Preferably, the nanoformulation is selected from CuSe-PEG-GOx, CuS-PEG-GOx, CuTe-PEG-GOx, TeSe-PEG-GOx, Ag 2 Se-PEG-GOx, FeSe-PEG-GOx.
[0021] More preferably, the nanoformulation is selected from CuSe-PEG-GOx.
[0022] The present invention also discloses a method for preparing a nano preparation, comprising the following steps:
[0023] S1. Preparing nanoparticles, comprising the following steps:
[0024] S11, dissolving a non-metallic source and sodium borohydride in water according to a proportion to form a non-metallic precursor; the non-metallic source is selected from substances that can be reduced to form -2-valent sulfur, selenium, and tellurium;
[0025] S12, adding the metal source to the non-metal precursor solution in step S11, reacting at room temperature, centrifuging and washing after sufficient reaction, to obtain M m X-PEG solution;
[0026] The metal source is selected from the group consisting of Cu 2+ 、Ag + , Fe 2+ of substances;
[0027] The M is a metal element, m is 1 or 2, and the selection of m is based on the valence state of the metal M;
[0028] The X is selected from non-metallic elements S, Se, Te;
[0029] Preferably, M is selected from Cu, Ag, Fe;
[0030] S2, preparing a nano preparation, comprising the following steps:
[0031] S21, to improve water solubility, the nanoparticles prepared in step S1 were mixed with NH 2 -PEG-SH were mixed in a certain ratio to prepare M m X-PEG solution;
[0032] S22, activating glucose oxidase with EDC and NHS;
[0033] S23, configure the M in step S21 m The X-PEG solution was mixed with the solution activated in step S22, and the mixture was fully reacted. After the reaction was completed, the supernatant was discarded by centrifugation, and the precipitate was retained and washed to prepare an antibacterial composite material M of a certain concentration. m X-PEG-GOx.
[0034] Preferably, the non-metallic source is a single substance of S, Se, or Te, which can reduce the amount of sodium borohydride used and will not introduce other impurity elements.
[0035] Furthermore, the metal source is a metal oxide or a salt.
[0036] Preferably, the metal source is cubic Cu 2 O nanoparticles.
[0037] Furthermore, the metal source is cubic Cu 2 When the nanoparticles are O, the step S1 further comprises the step S13:
[0038] S13, adding the precipitate washed in step S12 into ammonia water, centrifuging to collect the precipitate after the reaction is completed, and freeze-drying to obtain cubic hollow CuSe nanoparticles after washing;
[0039] This step is used to elute the unreacted cubic Cu 2 O nanoparticles to obtain cubic hollow CuSe nanoparticles.
[0040] Preferably, in step S11, the ratio of selenium powder to sodium borohydride is 1:1-2 by mass fraction.
[0041] More preferably, in step S11, the ratio of selenium powder to sodium borohydride is 1:1.5 by mass fraction.
[0042] Further, in step S12, the cubic Cu 2 O nanoparticles are prepared according to the following steps: copper sulfate pentahydrate, sodium hydroxide, sodium citrate and ascorbic acid are mixed and reacted at room temperature.
[0043] Preferably, in terms of mass fraction, Cu in step S12 is 2 The mass ratio of O to selenium powder is 1:1.1.
[0044] Preferably, in step S12, the centrifugation conditions are a rotation speed of 8000-10000 rpm and a centrifugation time of 10-15 min.
[0045] Preferably, in step S13, the freeze-drying temperature is -50°C to -54°C, and the drying time is 1 to 2 days.
[0046] Preferably, the concentration of aqueous ammonia in step S13 is 5 to 15% by mass.
[0047] More preferably, the concentration of aqueous ammonia in step S13 is 10% by mass.
[0048] Preferably, in step S23, the reaction temperature is 50° C. and the reaction time is 2 h; the centrifugal washing conditions are a rotation speed of 8000-10000 rpm and a centrifugal time of 10-15 min.
[0049] Preferably, the activation time in step S22 is 8 hours.
[0050] Preferably, the reaction time in step S23 is 24 h.
[0051] Preferably, in step S23, the ratio of GOx to CuSe-PEG is 1:3 by mass fraction.
[0052] The beneficial effects of the present invention are:
[0053] 1. The cubic hollow nanoparticles provided by the present invention work synergistically with GOx to degrade glucose to produce hydrogen peroxide, while M m X nanoparticles can react with hydrogen peroxide to produce ·OH and catalyze O 2 A variety of ROS were produced, and the composite material had a good bactericidal effect on Staphylococcus aureus, Escherichia coli, and drug-resistant bacteria when the concentration was 25 μg / mL;
[0054] 2. Nanomaterials can effectively consume the reducing agent glutathione in bacteria;
[0055] 3. Through the synergistic effect with glucose oxidase, it not only lowers blood sugar levels, but also produces active oxygen through the generated hydrogen peroxide to kill bacteria;
[0056] 4. Simple preparation process and high product stability BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 Cubic Cu 2 Transmission electron microscopy (TEM) image of O nanoparticles;
[0058] Figure 2 Transmission electron microscopy (TEM) images of cubic hollow CuSe nanoparticles;
[0059] Figure 3 Transmission electron microscopy (TEM) image of CuS nanoparticles;
[0060] Figure 4 Transmission electron microscopy (TEM) images of CuTe nanoparticles;
[0061] Figure 5 Transmission electron microscopy (TEM) image of TeSe heterostructure;
[0062] Figure 6 Ag 2 Transmission electron microscopy (TEM) images of Se nanoparticles;
[0063] Figure 7 Transmission electron microscopy (TEM) image of FeSe nanoparticles;
[0064] Figure 8 Particle size diagram of CuSe-PEG-GOx;
[0065] Fig. 9 Potential diagrams of CuSe, CuSe-PEG, and CuSe-PEG-GOx;
[0066] Fig.10 Data graph of hydroxyl radical generation of CuSe-PEG-GOx;
[0067] Fig.11 Active oxygen EPR pattern of CuSe-PEG;
[0068] Fig.12 Glutathione consumption graph of CuSe-PEG-GOx;
[0069] Fig.13 pH reduction data of glucose (Glu) degradation by CuSe-PEG-GOx;
[0070] Fig.14Hemolysis percentage after co-incubation of different concentrations of CuSe-PEG-GOx with mouse red blood cells;
[0071] Fig.15 Actual photos of the plates showing the killing of E. coli and drug-resistant E. coli by Glu, CuSe-PEG, CuSe-GOx and the control group;
[0072] Fig.16 Actual photos of the plates showing the killing of Staphylococcus aureus and drug-resistant Staphylococcus aureus by Glu, CuSe-PEG, CuSe-GOx and the control group;
[0073] Fig.17 Photos of the plates showing the killing of Escherichia coli and Staphylococcus aureus by Glu, CuS, CuS-PEG-GOx and the control group (blank);
[0074] Fig.18 Photos of the plates showing the killing of Escherichia coli and Staphylococcus aureus by Glu, CuTe, CuTe-PEG-GOx and the control group (blank);
[0075] Fig.19 Photos of the plates showing the killing of Escherichia coli and Staphylococcus aureus by Glu, TeSe, TeSe-PEG-GOx and the control group (blank);
[0076] Fig. 20 Glu、Ag 2 Se, Ag 2 Photos of plates showing Se-PEG-GOx and the control group (blank) killing Escherichia coli and Staphylococcus aureus;
[0077] Fig.21 Actual photos of the plates showing the killing of Escherichia coli and Staphylococcus aureus by Glu, FeSe, FeSe-PEG-GOx and the control group (blank). DETAILED DESCRIPTION
[0078] The specific implementation modes of the present invention are further described below in conjunction with examples. The following examples are only used to more clearly illustrate the technical embodiments of the present invention and are not intended to limit the protection scope of the present invention.
[0079] Example 1
[0080] 0.375 g of copper sulfate pentahydrate, 0.15 g of sodium citrate trihydrate, and 1 g of sodium hydroxide were mixed and added to 100 mL of ultrapure water to form aqueous solution A;
[0081] Weigh 0.264 g of ascorbic acid and add 50 mL of ultrapure water to form aqueous solution B;
[0082] The aqueous solution B is slowly added dropwise to the aqueous solution A and reacted at room temperature for 40 minutes. After the reaction, the precipitate is washed by centrifugation at 8000 rpm and freeze-dried for 1 to 2 days to form red cubic cuprous oxide nanoparticles.
[0083] The prepared Cu 2 TEM images of O nanoparticles are shown in Figure 1 As shown in the figure, it can be seen that the cuprous oxide nanoparticles are in regular cubic shape, are evenly dispersed, and have an average size of about 450nm.
[0084] Weigh 0.1579g of selenium powder and 0.24g of sodium borohydride and add 13mL of ultrapure water, react vigorously at room temperature for 5min to form a transparent sodium selenide solution, weigh 0.144g of freeze-dried cuprous oxide and add it to 50mL of ultrapure water, ultrasonically disperse it evenly, add the above sodium selenide solution to the dispersed cuprous oxide solution, react at room temperature for 13min, centrifuge at 8000rpm for 10min after the reaction, and retain the precipitate. After centrifugation and washing three times, add it to 100mL of 10% ammonia water for etching, the reaction temperature is 50℃, the reaction time is 2h, and after the reaction, centrifuge the precipitate again, wash the precipitate three times, and freeze-dry it for 1-2 days to obtain cubic hollow copper selenide nanoparticles, named CuSe NPs.
[0085] The TEM images of the prepared CuSe NPs are shown in Figure 2 shown.
[0086] In order to improve the water solubility of CuSe NPs, CuSe NPs were mixed with NH 2 -PEG-SH was added to ultrapure water at a ratio of 1:10 and stirred overnight to form a CuSe-PEG solution;
[0087] Glucose oxidase was activated by EDC and NHS for 8 hours to activate the -COOH group in the enzyme, and then 2 mL (1 mg / mL) of CuSe-PEG was added and stirred for 24 hours to load the enzyme. After the reaction, the supernatant was discarded by centrifugation at 80,000 rpm for 5 minutes, and the precipitate was washed three times. After washing, the solution was resuspended for standby use. The obtained precipitate was the antibacterial composite material, named CuSe-PEG-GOx.
[0088] Cu 2 O, CuSe, CuSe-PEG, and CuSe-PEG-GOx solutions were measured using a dynamic light scattering (DLS) instrument. The test results are shown in Figure 8 As shown, the average particle size (z-average) is 453, 473, 514.8, 546.9 nm, respectively, and the potential is negative ( Fig. 9shown).
[0089] Example 2
[0090] At room temperature and nitrogen atmosphere, 0.3 mmol NaBH 4 and 0.1mmol Na 2 S was dissolved in 9 mL of deionized water and mixed to prepare a selenium precursor solution.
[0091] Disperse 100 μL PAA in 90 mL deionized water and add 1 mL CuSO 4 The solution is reaction solution A.
[0092] The selenium precursor solution was added dropwise into the reaction solution A and stirred. The solution quickly turned dark green. After the reaction was completed, the precipitate was washed by centrifugation and dried to obtain CuS nanoparticles.
[0093] The TEM images of the prepared CuS NPs are shown in Figure 3 shown.
[0094] Example 3
[0095] At room temperature and under nitrogen atmosphere, 63.8 mg of tellurium powder was added into a three-necked flask containing 36 mL of ethanol and 12 mL of deionized water;
[0096] Weigh 56.75 mg NaBH 4 Dissolve in 2 mL of deionized water, add dropwise into a three-necked flask, stir at room temperature for 6 hours, and the solution turns red.
[0097] 134.45 mg CuCl 2 and 40 mg PVP were dissolved in 2 mL deionized water, stirred evenly, added to the flask, and the reaction was continued for 1.5 h. After the reaction, the product was centrifuged at 6000 rpm for 15 min, the supernatant was taken, dialyzed with a 100 KD dialysis bag for 48 h, the product was collected, and dried to obtain CuTe nanoparticles.
[0098] The TEM images of the prepared CuTe NPs are shown in Figure 4 shown.
[0099] Example 4
[0100] Weigh 0.2216g of sodium tellurite, sodium selenite, and 0.2g of polyvinyl pyrrolidone and add them to a mixed solution of 100mL of water, 10mL of hydrazine hydrate, and 10mL of ammonia water. Sinter at 100°C for 3h. After the reaction is completed, dialyze until the pH of the solution is neutral. Then take out the solution and freeze-dry it to obtain a TeSe heterojunction.
[0101] The TEM image of the prepared TeSe heterojunction is shown in Figure 5 shown.
[0102] Example 5
[0103] Preparation of deoxygenated water: Add a certain amount of deionized water into a three-necked flask, insert a glass tube into the rubber stopper and place it under the liquid surface to pass nitrogen for 30 minutes.
[0104] Pipette an appropriate amount of PA into 70 mL of deoxygenated water, using a concentration of 1 mol·L -1 NaOH solution and CH 3 COOH solution to adjust pH to 6, 7.5, or 9;
[0105] Add 5 mL of 50 mmol / L -1 AgNO 3 Solution and adjust pH value to make the solution clear and transparent and continue stirring;
[0106] 0.07 mmol of Na 2 SeO 3 The solid was dissolved in a certain volume of deoxygenated water and added dropwise to the above solution. The solution turned light yellow. Nitrogen was introduced throughout the process. As the reaction time increased, the solution color gradually deepened.
[0107] The mixed solution was placed at 90°C for reaction, and after the reaction was completed, it was quickly cooled to room temperature and the obtained brown clear liquid was ultrafiltered and centrifuged; the obtained concentrated solution was washed 3 times, the concentrated solution was collected, and it was quickly placed in liquid nitrogen for freezing for 2 minutes, and the frozen liquid was freeze-dried to obtain Ag after drying. 2 Se nanoparticles.
[0108] The prepared Ag 2 TEM images of Se NPs are shown in Figure 2. Figure 6 shown.
[0109] Example 6
[0110] 160 mg BSA was dissolved in 80 mL deionized water. After all the BSA was dissolved, 0.4 mmol·L -1 Ascorbic acid solution and 0.1mmol·L -1 Selenium dioxide solution, after stirring for 15 min, the solution turns into wine red selenium precursor;
[0111] Weigh 281.8 mg of ascorbic acid and 79.52 mg of ferrous chloride tetrahydrate and dissolve them in 4 mL of deionized water, add them to the selenium precursor solution, stir at room temperature for 24 hours, and after the reaction is completed, centrifuge the product at 10,000 rpm for 10 minutes to remove the precipitate. The supernatant is dialyzed with a dialysis bag with a cutoff of 14,000 for 3 days. After the dialysis is completed, the solution is freeze-dried to obtain FeSe nanoparticles.
[0112] The TEM image of the prepared FeSe NPs is shown in Figure 7 shown.
[0113] In order to further illustrate the mechanism of the beneficial effects of the present invention, the product prepared in Example 1 was subjected to the following test:
[0114] Test Example 1
[0115] In order to study the free radical production effect of CuSe-PEG-GOx, o-phenylenediamine was used as a chromogenic substrate, and different concentrations of CuSe-PEG-GOx, hydrogen peroxide (final concentration of 1 mM), and o-phenylenediamine (final concentration of 1 mM) were added to PBS buffer solution, respectively. The reaction was carried out in a shaker at 37°C in the dark for 30 minutes. After the reaction was completed, the spectrum of each group of CuSe-PEG-GOx was measured by a UV-visible spectrophotometer (as shown in Figure 10).
[0116] according to Fig.10 It can be seen that CuSe-PEG-GOx has a good effect in generating ·OH.
[0117] Test Example 2
[0118] Using DMPO and TEMP as capture agents, the EPR resonance spectrometer was used to prove that ·OH, 1 O 2 , ·O 2- The production of.
[0119] The reaction system of the experiment: 1mM H 2 O 2 , 100 mM DMPO / TEMP, the reactions were carried out in acetate buffer solution with a pH of 4.0, and the EPR spectrum of CuSe-PEG was recorded using a spectrometer (as shown in Figure 11).
[0120] Test Example 3
[0121] The consumption of the reducing agent glutathione (GSH) in bacteria by CuSe-PEG was studied.
[0122] Using DTNB (5,5′-dithiobis(2-nitrobenzoic acid) as an indicator, different concentrations of CuSe-PEG and GSH (final concentration of 0.3 mM) were added to PBS buffer solution, and the mixture was allowed to stand for 1 h in the dark. After the reaction, the mixture was centrifuged and DTNB (final concentration of 0.2 mM) was added to the supernatant. After two minutes, the spectra of each group of CuSe-PEG-GOx were measured using a UV-visible spectrophotometer (see Figure 2). Fig.12 shown).
[0123] according to Fig.12It can be seen that CuSe-PEG has a good effect on the consumption of glutathione.
[0124] Test Example 4
[0125] To monitor the pH change of glucose consumption by the material, a certain concentration of CuSe-PEG-GOx was added to a glucose solution dissolved in PBS (1mM, initial pH = 7.2). The final concentrations of CuSe-PEG-GOx and glucose were 25μg / mL and 125mM, respectively. The pH value was recorded with a real-time pH meter. Fig.13 This is a graph of glucose consumption data.
[0126] Test Example 5
[0127] The in vitro biocompatibility of the synergistic therapeutic system was evaluated by hemolysis assay.
[0128] Collect 1mL of mouse blood in an anticoagulant tube and centrifuge it at 8000rpm for 10min. After centrifugation, discard the supernatant and keep the red blood cells. The red blood cells were washed with PBS and resuspended in 10mL of PBS solution. Different concentrations of CuSe-PEG-GOx solutions (6.25μg / mL, 12.5μg / mL, 25μg / mL, 50μg / mL, 100μg / mL) were prepared as the experimental group, PBS as the negative control group, and ultrapure water as the positive control group. 200μL of red blood cell suspension was mixed with 800μL of each group of solutions and incubated at room temperature for 4h. After incubation, centrifuge, measure the ultraviolet absorbance of the supernatant and calculate the hemolysis percentage of red blood cells.
[0129] Fig.14 This is a data graph of the hemolysis percentage after incubation of CuSe-PEG-GOx solution with mouse red blood cells at various concentrations. It can be seen from the figure that even if the concentration of the experimental group reaches 100μg / mL, the hemolysis percentage of the nanomaterial is only 4.03%, and the hemolysis amount is negligible, indicating that the material has good biocompatibility.
[0130] In order to further illustrate the beneficial effects of the present invention, the following application examples and comparative examples are made for the product prepared in Example 1:
[0131] Application Example 1
[0132] Escherichia coli in logarithmic growth phase and drug-resistant Escherichia coli were diluted to OD600 = 0.5 colony forming unit (CFU) in LB liquid medium, and then diluted 10 times to 10 7 CFU / mL as working suspension.
[0133] 500 μL of a 10 7The CFU / mL bacterial solution and 500 μL CuSe-PEG-GOx were mixed and incubated at 37°C in a shaker for 1 h, and the final volume was 1 mL.
[0134] After the incubation, take 100 μL of the treated bacterial solution and dilute it 100 times with PBS. Take 100 μL of the diluted bacterial solution and spread it evenly on the plate using coating beads. Place the plate in a 37°C constant temperature incubator and incubate it for 12 hours before counting the number of colonies.
[0135] Application Example 2
[0136] In Application Example 1, replace “Escherichia coli” with “drug-resistant Escherichia coli”, and keep other conditions unchanged.
[0137] Comparative Examples 1-2
[0138] Compared with Application Example 1, Comparative Example 1 only replaces CuSe-PEG-GOx with CuSe-PEG;
[0139] Compared with Application Example 1, Comparative Example 2 is just a case of replacing CuSe-PEG-GOx with Glu group.
[0140] Compared with Application Example 1, Comparative Example 3 is only that CuSe-PEG-GOx replaces the blank group.
[0141] Comparative Examples 4 to 6
[0142] Compared with Application Example 2, Comparative Example 4 only replaces CuSe-PEG-GOx with CuSe-PEG;
[0143] Compared with Application Example 2, Comparative Example 5 is just a case of replacing CuSe-PEG-GOx with Glu group.
[0144] Compared with Application Example 2, Comparative Example 6 is just a case where CuSe-PEG-GOx replaces the blank group.
[0145] In order to test the beneficial effects, the following tests were conducted on Examples 1 to 2 and Comparative Examples 1 to 4: the growth of different bacteria (E. coli, drug-resistant E. coli) treated differently in solid culture medium. Fig.15 As shown:
[0146] It can be seen that the CuSe-PEG-GOx solution has a good antibacterial effect, indicating that the active oxygen produced by the material can destroy the bacterial cell membrane, and the bacterial survival rate was calculated to evaluate the antibacterial effect of each group of materials.
[0147] Bacterial survival rate (%) = number of bacterial colonies in the experimental group / number of bacterial colonies in the control group × 100%. It can be seen from the figure that compared with the number of bacteria in the control group without material treatment, the survival rate of the two bacteria in the Glu group was 100%, and the survival rates of the two bacteria in the CuSe-PEG group were 2.2% and 3.29%; the survival rates of the two bacteria in the CuSe-PEG-GOx+Glu group were both 0%.
[0148] Application Example 3
[0149] Staphylococcus aureus in the logarithmic growth phase was diluted to OD600 = 0.5 colony forming units (CFU) in LB liquid medium, and then diluted 10 times to 10 7 CFU / mL as working suspension.
[0150] 500 μL of a 10 7 The CFU / mL bacterial solution and 500 μL CuSe-PEG-GOx were mixed and incubated in a shaker at 37°C for 1 h, and the final volume was 1 mL.
[0151] After the incubation, take 100 μL of the treated bacterial solution and dilute it 100 times with PBS. Take 100 μL of the diluted bacterial solution and spread it evenly on the plate using coating beads. Place the plate in a 37°C constant temperature incubator and incubate it for 12 hours before counting the number of colonies.
[0152] Application Example 4
[0153] In Application Example 3, "Staphylococcus aureus" is replaced by "resistant Staphylococcus aureus", and other conditions remain unchanged.
[0154] Comparative Examples 7-9
[0155] Compared with Application Example 3, Comparative Example 7 only replaces CuSe-PEG-GOx with CuSe-PEG;
[0156] Compared with Application Example 3, Comparative Example 8 is just a case of replacing CuSe-PEG-GOx with Glu group.
[0157] Compared with Application Example 3, Comparative Example 9 is just a case where CuSe-PEG-GOx replaces the blank group.
[0158] Comparative Examples 10-12
[0159] Compared with Application Example 4, Comparative Example 10 is just to replace CuSe-PEG-GOx with CuSe-PEG;
[0160] Compared with Application Example 4, Comparative Example 11 is only that CuSe-PEG-GOx is replaced by Glu group.
[0161] Compared with Application Example 4, Comparative Example 12 is only that CuSe-PEG-GOx replaces the blank group.
[0162] In order to test the beneficial effects, the following tests were performed on Examples 3 to 4 and Comparative Examples 7 to 12: The plates were taken out the next day, the growth of the colonies on the plates was observed, the colonies were counted, and the bacterial survival rate was calculated to evaluate the antibacterial effect of each group of materials.
[0163] like Fig.16 The figure shows the growth of different bacteria (Staphylococcus aureus, resistant Staphylococcus aureus) after different treatments in solid culture medium. It can be seen that the CuSe-PEG-GOx solution has a good antibacterial effect, indicating that the active oxygen produced by the material can destroy the bacterial cell membrane. The bacterial survival rate was calculated to evaluate the antibacterial effect of each group of materials.
[0164] Fig.16 Actual photos of the plates showing Glu, CuSe-PEG, CuSe-PEG-GOx+Glu and the control group killing Staphylococcus aureus and drug-resistant Staphylococcus aureus.
[0165] from Fig.16 It can be seen that compared with the number of bacteria in the control group without material treatment, the survival rate of the two bacteria in the Glu group was 100%, and the survival rates of the two bacteria in the CuSe-PEG group were 2.47% and 2.89% respectively; the survival rates of the two bacteria in the CuSe-PEG-GOx+Glu group were both 0%.
[0166] In order to test the nanoformulation M prepared by the products of other examples m The sterilization effect of X-PEG-GOx is shown in the following application examples and comparative examples:
[0167] Application Example 4
[0168] Test the sterilization effect of CuS-PEG-GOx (CuS NPs) on Escherichia coli (S. aureus):
[0169] The product of Example 2, CuS-PEG-GOx (CuS NPs), was substituted for the CuSe-PEG-GOx in Application Example 1, and other conditions were the same as those in Application Example 1. The specific operation was as follows:
[0170] Escherichia coli in logarithmic growth phase and drug-resistant Escherichia coli were diluted to OD600 = 0.5 colony forming unit (CFU) in LB liquid medium, and then diluted 10 times to 10 7 CFU / mL as working suspension.
[0171] 500 μL of a 10 7The CFU / mL bacterial solution and 500 μL CuS-PEG-GOx were mixed and incubated at 37°C in a shaker for 1 h, and the final volume was 1 mL.
[0172] After the incubation, take 100 μL of the treated bacterial solution and dilute it 100 times with PBS. Take 100 μL of the diluted bacterial solution and spread it evenly on the plate using coating beads. Place the plate in a 37°C constant temperature incubator and incubate it for 12 hours before counting the number of colonies.
[0173] Test the sterilization effect of CuS-PEG-GOx (CuS NPs) on Staphylococcus aureus (E.Coli):
[0174] The product of Example 2, CuS-PEG-GOx (CuS NPs), was substituted for the CuSe-PEG-GOx in Application Example 3, and other conditions were the same as those in Application Example 3. The specific operation was as follows:
[0175] Staphylococcus aureus in the logarithmic growth phase was diluted to OD600 = 0.5 colony forming units (CFU) in LB liquid medium, and then diluted 10 times to 10 7 CFU / mL as working suspension.
[0176] 500 μL of a 10 7 The CFU / mL bacterial solution and 500 μL CuS-PEG-GOx were mixed and incubated at 37°C in a shaker for 1 h, and the final volume was 1 mL.
[0177] After the incubation, take 100 μL of the treated bacterial solution and dilute it 100 times with PBS. Take 100 μL of the diluted bacterial solution and spread it evenly on the plate using coating beads. Place the plate in a 37°C constant temperature incubator and incubate it for 12 hours before counting the number of colonies.
[0178] Comparative Examples 10 to 12
[0179] Comparative Example 10 is compared with Application Example 4, except that CuS-PEG-GOx is replaced with blank;
[0180] Compared with Application Example 4, Comparative Example 11 only replaces CuS-PEG-GOx with Glu;
[0181] Compared with Application Example 4, Comparative Example 12 is only that CuS-PEG-GOx is replaced by CuS.
[0182] The experimental results of Application Example 4 and Comparative Examples 10 to 12 are shown in the attached Fig.17 As shown, by comparison, it can be seen that CuS-PEG-GOx has the best sterilization effect, CuS has the second best sterilization effect, and Glu has basically no effect (equivalent to the blank group).
[0183] Application Example 5
[0184] The difference between Application Example 5 and Application Example 4 is that the product of Example 3, CuTe-PEG-GOx (CuTe NPs), is substituted for the CuS-PEG-GOx in Application Example 4, and the other conditions are the same.
[0185] Comparative Examples 13 to 15
[0186] Comparative Example 13 is compared with Application Example 5, except that CuTe-PEG-GOx is replaced with blank;
[0187] Compared with Application Example 5, Comparative Example 14 only replaces CuTe-PEG-GOx with Glu;
[0188] Compared with Application Example 5, Comparative Example 15 is the case where CuTe-PEG-GOx is simply replaced with CuTe.
[0189] The experimental results of Application Example 5 and Comparative Examples 13 to 15 are shown in the attached Fig.18 As shown, by comparison, it can be seen that CuTe-PEG-GOx has the best sterilization effect, CuTe has the second best sterilization effect, and Glu has basically no effect (equivalent to the blank group).
[0190] Application Example 6
[0191] The difference between Application Example 6 and Application Example 4 is that the product TeSe-PEG-GOx (TeSe NPs) of Example 4 replaces the CuS-PEG-GOx in Application Example 4, and other conditions are the same.
[0192] Comparative Examples 16 to 18
[0193] Comparative Example 16 is compared with Application Example 6, except that TeSe-PEG-GOx is replaced with blank;
[0194] Compared with Application Example 6, Comparative Example 17 only replaces TeSe-PEG-GOx with Glu;
[0195] Compared with Application Example 6, Comparative Example 18 is the case in which TeSe-PEG-GOx is simply replaced by TeSe.
[0196] The experimental results of Application Example 6 and Comparative Examples 16 to 18 are shown in the attached Fig.19 As shown, by comparison, it can be seen that TeSe-PEG-GOx has the best sterilization effect, TeSe has the second best sterilization effect, and Glu has basically no effect (equivalent to the blank group).
[0197] Application Example 7
[0198] The difference between Application Example 7 and Application Example 4 is that the product Ag of Example 5 is 2 Se-PEG-GOx(Ag2 Se NPs) replaced the CuS-PEG-GOx in Application Example 4, and the other conditions were the same.
[0199] Comparative Examples 19 to 21
[0200] Comparative Example 19 is compared with Application Example 7, except that Ag 2 Se-PEG-GOx was replaced with blank;
[0201] Comparative Example 20 is compared with Application Example 7, except that Ag 2 Se-PEG-GOx was replaced by Glu;
[0202] Comparative Example 21 is compared with Application Example 7, except that Ag 2 Se-PEG-GOx replaced by Ag 2 Se.
[0203] The experimental results of Application Example 7 and Comparative Examples 19 to 21 are shown in the attached Fig. 20 As shown, by comparison, we can see that: Ag 2 Se-PEG-GOx has the best sterilization effect, Ag 2 The sterilization effect of Se was second, and Glu had basically no effect (equivalent to the blank group).
[0204] Application Example 8
[0205] The difference between Application Example 8 and Application Example 4 is that the product FeSe-PEG-GOx (FeSe NPs) of Example 6 replaces the CuS-PEG-GOx in Application Example 4, and other conditions are the same.
[0206] Comparative Examples 22 to 24
[0207] Comparative Example 22 is compared with Application Example 8, except that FeSe-PEG-GOx is replaced with blank;
[0208] Compared with Application Example 8, Comparative Example 23 only replaces FeSe-PEG-GOx with Glu;
[0209] Compared with Application Example 8, Comparative Example 24 is only that FeSe-PEG-GOx is replaced by FeSe.
[0210] The experimental results of Application Example 8 and Comparative Examples 19 to 21 are shown in the attached Fig. 20 As shown, by comparison, it can be seen that FeSe-PEG-GOx has the best sterilization effect, FeSe has the second best sterilization effect, and Glu has basically no effect (equivalent to the blank group).
[0211] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A nano preparation of a drug for treating bacterial infection of diabetic wounds, characterized in that: The molecular formula is M m X-PEG-GOx; The M m X is a cubic hollow structure; The M is a metal element, m is 1 or 2, and the selection of m is based on the valence state of the metal M; The X is selected from non-metallic elements S, Se, and Te.
2. The nanoformulation according to claim 1, characterized in that M is selected from Cu, Ag, and Fe.
3. The nanoformulation according to claim 1, characterized in that The nanoformulation is selected from cubic hollow CuSe-PEG-GOx, CuS-PEG-GOx, CuTe-PEG-GOx, TeSe-PEG-GOx, Ag2Se-PEG-GOx, and FeSe-PEG-GOx.
4. Use of the nanoformulation according to any one of claims 1 to 3 for preparing a drug for treating bacterial infection of diabetic wounds.
5. The use of the nano preparation according to claim 4 for preparing a drug for treating bacterial infection of diabetic wounds, characterized in that: The nanoformulation uses cubic hollow CuSe-PEG-GOx.
6. A method for preparing a nano preparation, characterized in that: The steps include: S1. Preparing nanoparticles, comprising the following steps: S11, dissolving a non-metallic source and sodium borohydride in water according to a proportion to form a non-metallic precursor; the non-metallic source is selected from substances that can be reduced to form -2-valent sulfur, selenium, and tellurium; S12, adding the metal source to the non-metal precursor solution in step S11, reacting at room temperature, centrifuging and washing after sufficient reaction, to obtain M m X-PEG solution; The metal source is selected from the group consisting of Cu 2+ 、Ag + , Fe 2+ of substances; The M is a metal element, m is 1 or 2, and the selection of m is based on the valence state of the metal M; The X is selected from non-metallic elements S, Se, Te; The M is selected from Cu, Ag, and Fe; S2, preparing a nano preparation, comprising the following steps: S21, in order to improve the water solubility, the nanoparticles prepared in step S1 were mixed with NH2-PEG-SH in a certain ratio to prepare M m X-PEG solution; S22, activating glucose oxidase with EDC and NHS; S23, configure the M in step S21 m The X-PEG solution was mixed with the solution activated in step S22, and the mixture was fully reacted. After the reaction was completed, the supernatant was discarded by centrifugation, and the precipitate was retained and washed to prepare an antibacterial composite material M of a certain concentration. m X-PEG-GOx.
7. The method for preparing a nanoparticle preparation according to claim 6, characterized in that: The non-metallic source is single substance of S, Se and Te.
8. The method for preparing a nanoparticle preparation according to claim 6, characterized in that: The metal source is cubic Cu2O nanoparticles.
9. The method for preparing a nanoparticle preparation according to claim 8, characterized in that: The method comprises the following steps: when the metal source is cubic Cu2O nanoparticles, the step S1 also comprises the step S13: S13, adding the precipitate washed in step S12 into ammonia water, centrifuging to collect the precipitate after the reaction is completed, and freeze-drying to obtain cubic hollow CuSe nanoparticles after washing; This step is used to elute the unreacted cubic Cu2O nanoparticles to obtain cubic hollow CuSe nanoparticles.
Citation Information
Cited By
Intelligent hydrogel based on copper sulfide nano material, preparation method and application
CN122251558A
A kind of intelligent hydrogel based on copper sulfide nanomaterial, preparation method and application
CN122251558B
